Why the study?
As guidelines extend TAVI indications to low-risk younger patients, managing issues such as bioprosthesis durability and subsequent valve dysfunction represents an emerging clinical challenge.
The management of younger (<75 years), low-risk patients with aortic stenosis undergoing TAVI presents a new clinical challenge, particularly concerning bioprosthesis durability and future interventions.
Answers are grounded in this paper and cite their sources.
May warrant caution selecting TAVI in younger low-risk patients; leaves open optimal durability and reintervention strategies.
The number of aortic stenosis patients in Western countries is increasing, along with better life conditions and expectancies. Presently, the volume of percutaneous transcatheter aortic valve implantations (TAVIs) is incessantly increasing, and has already overcome the surgical replacement procedure volume. According to the literature, TAVI is a feasible procedure even among low surgical risk patients, and American guidelines have extended the indications for TAVI, including shifting patient evaluations from high/low STS scores to old/young patients, a "paradigm shift" of aortic stenosis evaluation. As a result, low-risk young (<75 years-old) population management could be the next challenge in cardiology. To manage the life conditions of a 65 year old patient affected by aortic stenosis who is undergoing TAVI, one of the most crucial issue will be bioprosthesis durability and the appropriate intervention to make in cases of valve dysfunction or failure.
No takes yet. Share an insight, caveat, or question.
Virgili et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: